bluebird bio Announces Transition of Chief Financial Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
BlueBird Bio (BLUE) Post Quarter Update: Starbeam Trial Interim at AAN Next - Leerink
February 29, 2016 7:07 AM ESTLeerink Partners analyst, Jonathan Chang sees bluebird bio (NASDAQ: BLUE) gene therapy LentiGlobin as the key value driver for the stock with initial clinical proof-of-concept (POC) achieved in hemoglobinopathies and next clinical updates expected at the ASH annual meeting in Dec. Near term, positive Lenti-D interim Ph II/III data in ultra-rare Childhood Cerebral Adrenoleukodystrophy (CCALD) at the American Academy of Neurology (AAN) annual meeting (April 15-21) could represent important platform validation.
CCALD is a rare severe and progressive central nervous system (CNS) disease. While... More
